HomeCompareBRCTF vs NOBL

BRCTF vs NOBL: Dividend Comparison 2026

BRCTF yields 6.06% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRCTF wins by $6.9K in total portfolio value
10 years
BRCTF
BRCTF
● Live price
6.06%
Share price
$33.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.8K
Annual income
$891.01
Full BRCTF calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — BRCTF vs NOBL

📍 BRCTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRCTFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRCTF + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRCTF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRCTF
Annual income on $10K today (after 15% tax)
$514.84/yr
After 10yr DRIP, annual income (after tax)
$757.36/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, BRCTF beats the other by $545.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRCTF + NOBL for your $10,000?

BRCTF: 50%NOBL: 50%
100% NOBL50/50100% BRCTF
Portfolio after 10yr
$26.4K
Annual income
$570.39/yr
Blended yield
2.16%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRCTF buys
0
NOBL buys
0
No recent congressional trades found for BRCTF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRCTFNOBL
Forward yield6.06%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$29.8K$22.9K
Annual income after 10y$891.01$249.78
Total dividends collected$7.5K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BRCTF vs NOBL ($10,000, DRIP)

YearBRCTF PortfolioBRCTF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$11,306$605.69$10,917$217.08+$389.00BRCTF
2$12,737$639.98$11,903$221.48+$834.00BRCTF
3$14,303$673.84$12,962$225.68+$1.3KBRCTF
4$16,011$707.15$14,099$229.68+$1.9KBRCTF
5$17,871$739.83$15,319$233.49+$2.6KBRCTF
6$19,894$771.78$16,628$237.10+$3.3KBRCTF
7$22,090$802.93$18,033$240.53+$4.1KBRCTF
8$24,469$833.21$19,539$243.78+$4.9KBRCTF
9$27,045$862.59$21,154$246.86+$5.9KBRCTF
10$29,829$891.01$22,884$249.78+$6.9KBRCTF

BRCTF vs NOBL: Complete Analysis 2026

BRCTFStock

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.

Full BRCTF Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this BRCTF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRCTF vs SCHDBRCTF vs JEPIBRCTF vs OBRCTF vs KOBRCTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.